APAC IPOs & Placements, Aequitas Research

Nicholas Tan

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

Myungin Pharm Pre-IPO: Domestic Leader, Partial Monetization for Founders

Myungin Pharm Pre-IPO: Discount to Peers; Potential Succession Planning

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Myungin Pharmaceutical / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/myungin-pharmaceutical" target="_blank" data-smartkarma-citation="entities:45685:1" rel="noopener">Myungin Pharmaceutical (MYUNGIN KS)</a> raised around US$142m in its upcoming Korean IPO.</li>
<li>It specializes in central nervous system (CNS) therapeutics, with strong technological expertise in developing and producing prescription drugs for stroke, Parkinson’s disease, schizophrenia, and depression.</li>
<li>In this note, we talk about the firm's trading dynamics.</li>
</ul>



Myungin Pharmaceutical (MYUNGIN KS) raised around US$142m in its upcoming Korean IPO.
It specializes in central nervous system (CNS) therapeutics, with strong technological expertise in developing and producing prescription drugs for stroke, Parkinson’s disease, schizophrenia, and depression.
In this note, we talk about the firm's trading dynamics.


Myungin Pharma Pre-IPO: Strong Insti Subscription Rates